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We demonstrate that the levels of native as well as trans-
fected prion protein (PrP) are lowered in various cell lines ex-
posed to phosphorothioate oligodeoxynucleotides (PS-DNA)
and can be rapidly reverted to their normal amounts by re-
moval of PS-DNA. This transient modulation was independent
of the glycosylation state of PrP, and in addition, all three PrP
glycoforms were susceptible to PS-DNA treatment. Deletion of
the N-terminal domain (amino acids 23–99), but not of the
other domains of PrP, abrogated its PS-DNA-mediated down-
regulation. PrP versions localized in the mitochondria, cyto-
plasm, or nucleus were not modulated by PS-DNA, indicating
that PrP surface exposure is required for executing this effect.
Proteins that in their native forms were not responsive to PS-
DNA, such as thymocyte antigen 1 (Thy1), Doppel protein
(Dpl), green fluorescent protein (GFP), and cyan fluorescent
protein (CFP), became susceptible to PS-DNA-mediated
down-regulation following introduction of the N terminus of
PrP into their sequence. These observations demonstrate the
essential role of the N-terminal domain for promoting oligo-
nucleotide-mediated reduction of the PrP level and suggest
that transient treatment of cultured cells with PS-DNAmay
provide a general method for targeted modulation of the levels
of desired surface proteins in a conditional and reversible
manner.
Prion diseases are fatal neurodegenerative disorders caused
by the conversion of the cellular prion protein (PrPC)4 into its
infectious conformation, PrPSc (1). The accumulation of PrPSc
in the central nervous system results in neurodegeneration
and lethal disease progression by a mechanism that is still
unknown (2, 3). PrPC is a phylogenetically conserved protein
(4, 5), which is present in a wide range of cell types besides
neuronal cells and is localized mainly at the plasma mem-
brane, although cytosolic and nuclear localizations were de-
scribed (6). Nevertheless, prion disease pathogenesis seems to
depend on its membrane localization (7). Neuronal PrP was
demonstrated to play a role in neuroprotection (8) and to be
involved in cell signaling (9, 10). The important role attrib-
uted to PrP based on its prevalence is complicated by the ob-
servation that mice lacking PrP display normal development
and behavior (11). Recently, it was demonstrated that axonal
prion protein is required for peripheral myelin maintenance
(12). Thus, the physiological role of PrP is yet to be fully
elucidated.
PrPC proteins possess high ability to bind short nucleic acid
molecules regardless of their sequence, and it was suggested
that this DNA binding aptitude may be involved in the patho-
genicity of prion diseases (for a review, see Ref. 13). The use of
oligodeoxynucleotides as a modality of affecting PrPSc levels
was suggested by in vivo studies reported by Sethi et al. (14),
who have documented that co-inoculation of mice with pri-
ons and oligodeoxynucleotides significantly prolonged sur-
vival times. This effect was suggested to reflect the elimina-
tion of PrPSc following activation of the innate immune
response by the CpG motif in the oligodeoxynucleotides.
Other studies showed that prion pathogenesis can be pre-
vented by such treatments in the absence of the receptor that
specifically binds CpG oligonucleotides (15), suggesting that
the suppression of disease was not mediated by the activation
of the immune system through the CpG motif but more likely
by direct interaction of PrP with nucleic acids.
Modified oligodeoxynucleotides such as phosphorothioate
oligodeoxynucleotides (PS-DNA), which exhibit reduced en-
zymatic degradation, were shown to down-regulate levels of
both PrPSc and PrPC in mouse-scrapie cells and animal mod-
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els (16, 17). The ability to prevent or eliminate scrapie infec-
tivity in cell culture correlated with the size of PS-DNA (18-
mer) and was sequence-independent. Single-stranded and
double-stranded PS-DNA, but not PS-RNA, were equally able
to promote a drop in PrPSc levels and did not involve inhibi-
tion of the translation or transcription machinery but rather
an effect on preexisting PrP (16). Examination of the interac-
tion of PS-DNA with PrP established that PS-DNA may di-
rectly bind PrP and that PS-DNA may co-localize with inter-
nalized PrP in both infected and uninfected cells (18). This
suggested that the anti-scrapie effect of PS-DNA might not be
through interaction with PrPSc but rather with PrPC. PrP deg-
radation in the presence of PS-DNA is probably occurring at
the lysosome (14), and binding of PS-DNA to PrPC leads to its
increased internalization (18).
The studies documented in the present report further ex-
amine PrP down-regulation in response to PS-DNA exposure.
We demonstrate that the N terminus domain of PrP is essen-
tial for the susceptibility to PS-DNA-mediated diminution of
plasma membrane PrP levels in a variety of cell lines. Chime-
ric heterologous proteins, engineered to contain the PrP N
terminus, could be endowed with PS-DNA sensitivity, sug-
gesting that the PS-DNA induced down-regulation may serve
as the basis for a general method for modulation of protein
levels.
EXPERIMENTAL PROCEDURES
Plasmids—The following constructs were described previ-
ously: g1, g2, and g12 (19); mutants 1, 2, 3, 5, 12, and 25 (20,
21); CD4-PrP, NT-Thy1, and Thy1 (22); MoXenPrP (23); and
PrP targeted to the cytoplasm (CytoPrP) (24), the nucleus
(NucPrP), and the mitochondria (MitoPrP) (25). For cloning
of PrP-Thy1, a PCR fragment encompassing the GPI attach-
ment signal of murine Thy1 protein (amino acids 127–162)
was fused by standard cloning techniques to a truncated 3F4-
PrP comprising residues 1–231. All amino acid numbers refer
to the mouse PrP sequence (GenBankTM accession number
M18070). All plasmid constructs were sequenced using the
primers for sequence verification, and amplified in Esche-
richia coli (DH10B), kindly provided by Dr. Saul Burdman.
Treatment of Cells with Oligodeoxynucleotides—The follow-
ing purified PS oligodeoxynucleotides were purchased from
TriLink Biotechnologies (San Diego, CA): CpG 22-mer CpG-
PS-DNA, 5-TGACTGTGAACGTTCGAGTGA-3; and
Scrambled 22-mer SCR-PS-DNA, 5-CAGTGATAGCTATG-
TGAGCTAG-3. In all experiments, 10 M PS-DNA was
added to themedium for 24 h unless otherwise noted. Following
treatment of cells with oligodeoxynucleotides, cells were washed
with PBS, and 100l of lysis buffer (10mMTris-HCl, pH 8; 100
mMNaCl; 0.5%Nonidet P-40; and 0.5% deoxycholate) was added
to the 60-mm plates for 5 min on ice. DNA aggregates were col-
lected from the lysate using a sterile tip.
Cell Cultures and Transfections—Murine neuroblastoma
cell lines (N2a), Chinese hamster ovary cells (CHO), and hy-
pothalamic cell line infected with scrapie and stably trans-
fected with prion protein (ScGT1-MHM2) were kindly pro-
vided by Dr. Albert Taraboulos (16, 26). Human embryonic
kidney cells (HEK293) were purchased from ATCC. Cells
were grown, treated with oligodeoxynucleotides, harvested,
and maintained as described (13), unless otherwise noted. Cell
lines were grown in DMEMmedium enriched with 10% v/v
FBS (Kibbutz, Beth Ha’Emek, Israel), 1% v/v L-glutamine (Kib-
butz, Beth Ha’Emek, Israel), and 1% v/v penicillin-streptomy-
cin (Sigma); ScGT1 cells were grown in 50% v/v Opti-MEM
medium (Invitrogen), 43.5% DMEM, 5% v/v FCS, 0.5 v/v L-
glutamine, and 1% v/v penicillin-streptomycin. Transient
transfection of the cells was performed using the FuGENE kit
with 2 g of DNA construct per transfection. Seventy-two
hours after transfection, cells were exposed to PS-DNA. For
stable transfections, 72 h after transfection, cells were exposed
to selective medium containing 1 g/liter G418. Stably trans-
fected cells were established after a period of 3–4 weeks of
selection.
Antibodies and Immunoblots—Protein concentration in
each sample was determined using a Bradford reagent (Bio-
Rad). Samples were loaded onto 12% SDS-PAGE gels. In all
experiments, 100 g/well of total protein lysates was loaded,
unless otherwise noted. Prestained protein molecular weight
markers were purchased from Fermentas. Western blots were
generated by standard procedures (16). PrP was detected us-
ing Fab D13 (27) (InPro Biotechnology). Goat anti-human Fab
was used as secondary antibody (Pierce). Levels of transfected
PrP or PrP protein fusions containing the hamster PrP
epitope 109–112 (see Fig. 2c for location of this epitope) were
detected using the 3F4 (Sigma). Anti-tubulin and anti-actin
monoclonal antibodies were from Sigma. Blots probed with
monoclonal antibodies were developed using a goat anti-
mouse IgG. Levels of MoDpl, NT-Thy1, and Thy1 were de-
tected as described in Ref. 22. Levels of CytoPrP, NucPrP, and
MitoPrP were detected as described (24, 25). All secondary
antibodies were peroxidase-conjugated, enabling ECL visual-
ization of proteins.
Tunicamycin and Phosphatidylinositol Phospholipase C
(PIPLC) Treatments—Twenty-four hours following 1:10 split-
ting, the cells were washed, and 1.5 mg/ml tunicamycin was
added. PS-oligodeoxynucleotides were then added to the dish
for variable periods of time. PIPLC was diluted to a final con-
centration of 200 M with 0.05% BSA, 144 mM NaCl, 10 mM
Tris-HCl, pH 7.4. N2a cells were grown as described for oli-
godeoxynucleotide treatment. Oligodeoxynucleotides were
then added to the dish (10 M) for 72 h. Following extensive
washing, fresh serum-free medium in the presence or absence
of PIPLC (200 mM) was added for 6 h at 37 °C. PrP in the su-
pernatant was concentrated by TCA precipitation.
Densitometric Quantification and Statistics—Protein quan-
tification of Western blots was done using the NIH ImageJ
software. PrP signal was normalized to total protein present
on Coomassie Blue-stained gels, to tubulin, or to actin signals.
The data represent the average and S.D. of three independent
experiments for each treatment. Student’s t tests were per-
formed for two-group comparisons. For comparisons involv-
ing more than two groups, post hoc least squares difference
one-way analysis of variance was used. Treatments were con-
sidered to be significant when p 0.05.
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PrP Is Efficiently Degraded upon PS-DNA Treatment—The
phenomenon of native PrP down-regulation following PS-
DNA treatment was demonstrated in N2a and GT1 neuronal
mouse cell lines (16). To explore the possibility that this phe-
nomenon is of a broader nature, CHO cells transfected with
3F4PrP, a murine PrP containing hamster PrP epitope 109-
112 (CHO-3F4PrP), mouse neurocortical neuroblast cells
(TSM), and human kidney 293 cells, were exposed to 10 M
PS-DNA for 24 h, and the level of PrP in each case was in-
spected by Western blot analysis. Transfected murine PrP
contained the 3F4 epitope enabling specific immunodetection
of the transfected proteins but not of the endogenous mouse
PrP (see “Experimental Procedures”). Treatment resulted in a
significant decrease in the amount of native or recombinant
PrP in all cell lines (Fig. 1). PS-DNAs exhibiting two different
DNA sequences were used, CpG-PS-DNA and Scr-PS-DNA.
Treatment with either of these sequences generated identical
results verifying our initial observation that the PS-DNA-me-
diated PrP down-regulation is independent of the PS-DNA
sequence (16). We observed that shorter incubations (2 h) are
sufficient to promote significant lowering of PrP levels (50%
as compared with untreated cells, supplemental Fig. 3, com-
pare lane 2 with lane 1). Exposure to PS-DNA for 8 h was
more potent than the 4-h treatment (80% PrP level diminu-
tion, supplemental Fig. 1, compare lane 2 with lane 4). We
observed rapid restoration of the PrP levels following termi-
nation of the treatment, to 80% of the initial levels (supple-
mental Fig. 1, lane 3). A longer recovery time of 24 h fully re-
stored the PrP levels (supplemental Fig. 1, lane 6).
Glycosylation Is Not Essential for PS-DNA-mediated PrP
Down-regulation That Involves Existing as Well as Newly Syn-
thesized PrP—PrP is a glycosylated protein and therefore gen-
erates three electrophoretically distinct isoforms distin-
guished by molecular weight (mouse PrP harbors two
N-glycosylation sites at positions 180 and 196). To assess
whether this post-translation modification affects PrP down-
regulation mediated by PS-DNA, we examined N2a cells
transfected with three different mouse PrP recombinant ver-
sions (supplemental Fig. 2). In these PrP forms, each glycosy-
lation site or both of them were mutated, resulting in an al-
tered state of glycosylation. We observed that significant
down-regulation (50–80% reduction in the level of recombi-
nant PrP) occurs in all cases (supplemental Fig. 2), clearly in-
dicating that PrP glycosylation has no impact on PS-DNA-
mediated PrP down-regulation. Next, we addressed the
question whether de novo synthesis of PrP is involved in the
observed PS-DNA-mediated reduction in the level of PrP. To
distinguish between newly synthesized PrP and mature pre-
existing PrP, cells were exposed to tunicamycin, which inhib-
its the N-glycosylation of newly synthesized proteins (28).
Accordingly, mature glycosylated PrP forms can be detected
as upper higher molecular weight bands on Western blots,
whereas the newly synthesized nonglycosylated PrP consti-
tutes mainly the low molecular band. Both newly synthesized
as well as mature PrP were down-regulated in the presence of
PS-DNA (supplemental Fig. 3).
The N Terminus of PrP Is Essential for the PS-DNA-medi-
ated Down-regulation—To determine whether any specific
domain of PrP is essential for the reduction in the level of PrP,
PrP mutated versions entailing various deletions were trans-
fected into N2a cells (Fig. 2). The mutated versions of PrP
inspected were: mutant 5, exhibiting a deletion between aa
positions 23 and 88; mutant 12, exhibiting a deletion between
aa positions 141 and 176; and mutant 25, exhibiting two dele-
tions between aa positions 23 and 88 and positions 141 and
176. The data demonstrate that N terminus deletion, specifi-
cally residues 23–88, abolished the down-regulation of PrP in
response to PS-DNA treatment (Fig. 2a). To further map the
domain essential for this effect, three different versions of PrP
harboring different deletions within the N terminus were test-
ed: mutant 1, exhibiting a deletion between aa positions 48
and 91; mutant 2, exhibiting a deletion between aa positions
23 and 51; and mutant 3, exhibiting a deletion between aa
positions 68 and 90. These partial deletions did not affect the
reduction of PrP level, strongly indicating that an intact N
terminus is necessary for this phenomenon. The resistance of
the N-deleted PrP mutant could be reversed by fusing it with
the N terminus domain of Xenopus laevis PrP (Fig. 2b). We
note that some deletions conferred a higher susceptibility to
PS-DNA treatment as compared with the full-length PrP such
as in the case of the aa 68–90 domain removal (Fig. 2b, mu-
tant 3 as compared with mutant 1). This issue needs further
investigation, and we conclude that the N terminus integrity
is essential for the PS-DNA-mediated down-regulation.
Plasma Membrane Localization Is Essential for Reduction
in the Level of PrP—Subcellular localization of PrP can be
controlled by exploiting recombinant versions of PrP, which
are targeted specifically to the nucleus, mitochondria, cyto-
plasm, or cell surface of the cells. Accordingly, PrP targeting
to the nucleus or mitochondria may be achieved by replacing
its endoplasmic reticulum signal sequence with the nuclear
localization signal of SV40 large T antigen or the mitochon-
drial signal sequence of subunit 1 of the ubiquinol cyto-
chrome c reductase complex, respectively (25). Deletion of the
endoplasmic reticulum signal sequence leads to cytoplasmic
PrP expression (24). Using such PrP versions, we addressed
FIGURE 1.Native or transfected PrP proteins are down-regulated in var-
ious cell lines exposed to PS-DNA. a, Western blot analysis of N2a (mouse
neuroblastoma), TSM (mouse neurocortical neuroblasts), CHO-3F4PrP (CHO
cells stably transfected with mouse PrP containing the 3F4 PrP epitope),
ScGT-3F4PrP (scrapie-infected mouse hypothalamic neuronal cell line stably
transfected with 3F4PrP), and HEK 293 cells (human embryonic kidney). PrP
was detected using the D13 (lanes 1–4, 7, and 8) or the 3F4 (lanes 5, 6, 9, and
10) anti-PrP antibody.MW, molecular mass markers. b, densitometric quan-
tification of Western blot analyses (n three independent experiments,
p 0.001).
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the question whether a specific cellular localization of PrP is
essential for its down-regulation in the presence of PS-DNA.
CytoPrP, MitoPrP, and NucPrP of N2a cells, which are not
imported into the endoplasmic reticulum/Golgi, can be dis-
tinguished by the fact that they generate only one electropho-
retic band of unglycosylated PrP (Fig. 3a). Neither one of
these PrP versions were affected by the presence of PS-DNA,
as compared with positive controls entailing plasma mem-
brane-localized PrP (Fig. 3b). The notion that membrane lo-
calization is necessary and sufficient was substantiated by ex-
periments employing various membrane attachment
modalities, which may alter the PrP microenvironment on the
plasma membrane. This issue was examined by substituting
the GPI anchor attachment signal (aa 231–254) with either
the transmembrane mouse CD4 domain (PrP-CD4) or the
GPI of thymocyte antigen 1 (PrP-Thy1). The first modifica-
tion shifts PrP from the rafts/caveolae-like domain to a clath-
rin-coated pit trafficking environment (29, 30). The second
modification directs PrP to a different domain than PrP
within the lipid rafts (31, 32). These two replacements did not
affect the PS-DNA-mediated diminution, although the results
for PrP-CD4 construct were not statistically significant (Fig.
4). Therefore, the modality by which the protein is attached to
the membrane did not affect the reduction in PrP levels fol-
lowing exposure to PS-DNA.
Taken together, these experiments indicate that only PrP
localized at the outer leaflet of the plasma membrane inter-
acts with PS-DNA, leading to its level reduction. This conclu-
sion was strengthened by the observation that cells treated
with PS-DNA and subsequently exposed to PIPLC, which
cleaves all GPI membrane-associated molecules, released into
the medium significantly lower amounts of PrP. These results
indicate that the levels of membrane PrP were indeed reduced
in the presence of PS-DNA prior to the PIPLC-mediated
cleavage (supplemental Fig. 4, compare lane 1 with lane 3).
Attaching PrP at the N Terminus or C Terminus of Other
Proteins Leads to Their Down-regulation in the Presence of
PS-DNA in Cell Culture—We explored the possibility to pro-
mote reduction in the levels of other membrane proteins,
FIGURE 2. PrP N terminus is essential for PrP down-regulation in the presence of PS-DNA. a and b, Western blot analysis of PS-DNA-treated N2a cells
transiently transfected with various deletion-mutated forms of PrP.MW, molecular mass markers;Mut, mutation. c, schematic representation of PrP. SS, sig-
nal sequence; PO, pre-octarepeat domain; OR, octarepeat domain; GPI, glycosylphosphatidylinositol anchor. Deletions are indicated as open boxes contain-
ing the aa positions of their boundaries. d, densitometric quantification of Western blot analyses (n three independent studies, p 0.009 for mutants 1
and 12, p 0.0005 for MHM2, mutant 3, and mutant 2, and p 0.0008 for MoXenPrP).
FIGURE 3.Nuclear, cytosolic, andmitochondrial PrP are not down-regu-
lated in cells exposed to PS-DNA. a, Western blot analysis of N2a cells
transiently transfected with plasmid constructs directing PrP into different
cellular compartment.mtPrP, MitoPrP. b, densitometric quantification of
Western blot analyses (n three independent studies).
FIGURE 4.Different membrane-anchoringmodalities do not affect PS-
DNA-induced PrP down-regulation. a, Western blot analysis of N2a cells
transiently transfected with the indicated plasmid constructs. PrP-CD4, fu-
sion of PrP aa 1–230 and the transmembrane domain of mouse CD4 (aa
369–431); PrP-Thy1, fusion of PrP (aa 1–231) and the GPI anchor of Thy1 (aa
127–163); NT-Thy1, fusion of aa 1–22 of PrP, the FLAG epitope, PrP N termi-
nus (aa 23–88), and Thy1. Thy1 was detected using anti-HA antibodies, and
NT-Thy1 was detected using anti-FLAG antibodies. All other PrP forms were
detected using the 3F4 monoclonal antibody.MW, molecular mass markers.
b, densitometric quantification of Western blot analyses (n three inde-
pendent studies, p 0.0001, p 0.005, p 0.0004 for 3F4PrP, PrP-Thy1,
and for NT-Thy1, respectively).
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which are not affected by PS-DNA, by attaching the PrP N
terminus domain into their sequence. One of these proteins
previously shown to be resistant to PS-DNA treatment is Dpl
(16), despite the high degree of spatial homology that it shares
with PrP (33). We therefore used fusion products of different
portions of the PrP N terminus with different segments of the
C terminus of Dpl and addressed their modulation in N2a
cells upon PS-DNA exposure (Fig. 5c). The results indicate
that the levels of all PrP-Dpl protein fusions were lowered in
the presence of PS-DNA as compared with unaffected Dpl
levels (Fig. 5a). We then examined another recombinant pro-
tein fusion generated by addition of the N-terminal portion of
PrP to the protein Thy1 (PrP-Thy1), which does not share any
structural homology with PrP yet is a GPI-anchored mem-
brane protein. The data reveal that the chimeric form of Thy1
became susceptible to PS-DNA treatment due to the PrP N
terminus (Fig. 4a, compare lane 8 with lane 7). Furthermore,
we inquired whether the levels of proteins that are resistant to
PS-DNA and are not anchored to the cell surface in their na-
tive form could be lowered in the presence of PS-DNA if
tagged with the N terminus of PrP and anchored to the mem-
brane. Accordingly, we generated two chimeric molecules; the
first is a cyan fluorescent protein (CFP) recombinant form in
which CFP is inserted into PrP downstream of the signal se-
quence (Fig. 6c, SS) and upstream of the PrP N-terminal deg-
radation-mediating domain. The second molecule involved
similar modifications of the yellow fluorescent protein (YFP)
(Fig. 6c). Both PrP-CFP and PrP-YFP fusion proteins were
susceptible to PS-DNA treatment. This phenomenon was
observed both in N2a and in CHO cells (Fig. 6). We therefore
conclude that the levels of proteins with no structural homol-
ogy to PrP can be reduced by PS-DNA treatment when tagged
with the N terminus of PrP as long as they are anchored to the
cell membrane.
DISCUSSION
We and others documented in the past that PS-DNA treat-
ment of cells in culture reduces the levels of PrPSc and PrPC
and suggested that PS-DNA may serve as the basis for the
development of a future potent countermeasure for treatment
of prion diseases (16, 18, 34). The current study aims to assess
the essential factors needed for the observed modulatory ef-
fect of PS-DNA treatment on PrPC levels.
The current major observations are the essential role of the
N-terminal domain and the membranal localization of PrP for
the PS-DNA-mediated reduction. Testing different deletion-
mutated versions of PrP established that removal of its N ter-
minus (aa 23–90) resulted in loss of susceptibility to PS-DNA
treatment, whereas other deletions such as that of an essential
internal domain for prion infectivity (aa 141–176) had no ef-
fect. Furthermore, proteins that are resistant to PS-DNA ex-
posure became susceptible when tagged only with PrP N ter-
FIGURE 5. Attachment of PrP at the N terminus of the Dpl protein results
in susceptibility to PS-DNA. a, Western blot analysis of N2a cells tran-
siently transfected with different fusion products of PrP and Dpl.MW, mo-
lecular mass markers. b, densitometric quantification of Western blot analy-
ses (n three independent studies, p 0.04). c, schematic representation
of the fusion products examined. The aa positions of the boundaries of PrP
(gray boxes) and Dpl (dark boxes) are indicated in each case. SS, signal se-
quence; PO, pre-octarepeat domain; OR, octarepeat domain; GPI, glycosyl-
phosphatidylinositol anchor.
FIGURE 6. Attachment of PrP at the C terminus of the cytosolic proteins YFP and CFP promotes PS-DNA susceptibility. a, Western blot analysis of CHO
cells transiently transfected with CFP-PrP or YFP-PrP fusion products and treated with PS-DNA. (n two independent studies).MW, molecular mass mark-
ers. b, densitometric quantification of Western blot analyses in panel a. c, Western blot analysis of N2a cells transiently transfected with CFP-PrP or YFP-PrP
fusion products and treated with PS-DNA. d, positions of YFP or CFP insertion in PrP. SS, signal sequence; PO, pre-octarepeat domain; OR, octarepeat do-
main; GPI, glycosylphosphatidylinositol anchor.
Modulation of Protein Expression by Phosphorothioate DNA
MARCH 4, 2011•VOLUME 286•NUMBER 9 JOURNAL OF BIOLOGICAL CHEMISTRY 6915
 at M
ax Planck Institute of Im
m










minus. Thus, the proteins Dpl, Thy1, CFP, and YFP, which do
not share sequence homology with PrP and which in their
native form are not affected by PS-DNA, were reduced when
anchored to the cell surface and fused either to full-length PrP
or only to a portion of the N terminus of PrP. Moreover, pre-
liminary data suggest that PrP can be attached to the C termi-
nus of CFP and YFP proteins for PS-DNA susceptibility, with-
out any effect on their fluorescence. These observations are in
good agreement with previous studies demonstrating that
nucleic acid binding properties of PrP are confined to its N-
terminal region (35, 36).
Apart from DNA binding, the N terminus of PrP may bind
copper via an octarepeat peptide domain (37, 38), which re-
sides at position 48–90. We note that PS-DNA treatment of
cells transfected with a recombinant version of murine PrP in
which its native N-terminal domain (aa 1–90) was replaced
with the homologous sequence from X. laevis PrP (aa 1–69),
and therefore devoid of the copper-binding domain, resulted
in increased susceptibility to reduction in PrP levels. This ob-
servation may reflect the previously reported increased degra-
dation of PrP devoid of the copper-binding domain (39). On
the other hand, one may speculate that the copper-binding
domain may interfere with PS-DNA binding or that the struc-
ture of the N terminus devoid of the copper domain is more
amenable to interaction with PS-DNA. This issue needs to be
further investigated.
We demonstrate that PrP or heterologous proteins tailored
with the N-terminal domain of PrP have to be anchored to
the cell membrane for efficient reduction in response to PS-
DNA treatment of the cells. PrP proteins directed to the cyto-
sol, mitochondria, or nucleus became resistant to PS-DNA
exposure. The mode of anchoring to the cell surface and the
microenvironment of PrP on the cell surface does not influ-
ence its susceptibility to PS-DNA, as shown by efficient re-
duction in the levels of PrP versions in which the PrP GPI
anchor was replaced with the Thy1 GPI or with the CD4
transmembrane domain. Alteration of a different PrP post-
modification such as N-glycosylation does not seem to influ-
ence the PS-DNA effect, which efficiently occurred with
non-, mono-, and diglycosylated isoform, as well as following
tunicamycin treatment. These observations are somewhat
contradictory to the reported failure of partially glycosylated
PrP to be efficiently implanted in the cell surface (19, 40, 41),
suggesting that the exact involvement of glycosylation for the
migration of PrP to the surface and/or its stable localization at
the membrane are yet to be fully understood. We note that
Capellari et al. (42) suggested in the past that glycan occu-
pancy of the first PrP glycosylation does not appear to be es-
sential for its transport through the secretory pathway.
Based on the current study, we may only speculate on the
mechanism responsible for PrP down-regulation upon PS-
DNA exposure. One possible explanation invokes enhanced
internalization of PrP promoted by PS-DNA in line with the
reported internalization of PrP following exposure to poly-
amines (31, 43) and PS-DNA (18). Because no secreted forms
of PrP could be detected in the cell medium following PS-
DNA exposure, we suggest that PrP is internalized and de-
graded within the cells, as suggested previously (15). Prelimi-
nary results suggest that the polyanion suramin was not able
to block PrP down-regulation in the presence of PS-DNA,
indicating that these two negatively charged compounds are
probably down-regulating PrP levels by different mechanisms
and are not competing with the same binding domain on PrP
(not shown). Suramin was shown to induce misfolding of
plasma membrane PrP and depends on the proximity to the
C-terminal domain of PrP (31). Further studies will be neces-
sary to accurately distinguish between the different mecha-
nisms mediating PrP down-regulation in response to PS-DNA
(presumably involving internalization and degradation) as
opposed to suramin (which involves misfolding). An alterna-
tive, yet not mutually exclusive, mechanism may involve the
previously proposed unfolding of prion protein promoted by
interaction with DNA resulting in enhanced accessibility to
proteolytic degradation (44).
Previous studies demonstrated the in vivo anti-prion effect
of PS-DNA containing the CpG motif, suggesting that the
anti-prion effect may be due to the stimulation of the innate
immune response (14, 45). Other studies suggested that
down-regulation of PrPSc following exposure of PS-DNA is
due to the direct interaction of PS-DNA to PrPC (18). Fur-
thermore, Zou et al. (46) reported that an anti-DNA antibody
or the bacterial DNA-binding protein g5p co-captures PrP
from cell lysates in pulldown experiments, strengthening the
notion that DNA and PrP closely interact. Although the cur-
rent study cannot rule out the possibility that the observed
effect involves an additional, yet to be identified, molecule, it
provides strong evidence in support of the direct binding hy-
pothesis. Most notably, this phenomenon is shown to occur
equally efficiently in various cell lines of various histological
and phylogenetic origins, strongly suggesting that the interac-
tion of PS-DNA and PrP does not involve tissue-specific fac-
tors. Considering the possibility that PS-DNA treatment may
represent the basis for a future therapeutic approach, it will be
interesting to determine whether a similar diminution in the
PrP levels may be observed in cultures of primary neuronal
cells.
The study presented here suggests a novel method by
which membrane-located proteins can be down-regulated in a
controlled and transient manner in cell cultures. We detect
significant reduction in the protein levels following 2 h of in-
cubation in the presence of PS-DNA. This reduction may
gradually progress for extended incubation periods. More-
over, the effect is reversible, and removal of PS-DNA from the
medium results in restoration of PrP levels to normal values
within 4 h.
The approach that may be pursued according to this meth-
odology may involve the use of a PrP tag (28 amino acids of
PrP) fused to a protein of interest expressed in cell cultures.
Subsequently, similar to other specific gene-silencing experi-
mental setups, the physiological significance of the down-
regulation of the desired protein may be interrogated by a
variety of approaches. The method proposed here may be su-
perior to the siRNA approach for assaying physiological
events occurring short times after the specific removal of a
protein of interest (2–8 h) and especially by virtue of its rapid
and full restoration to normal levels. Obviously the recovery
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time following cessation of the treatment will depend on the
turnover of the protein under study, which may differ sub-
stantially from case to case. Nevertheless, other approaches,
such as siRNA-mediated inhibition of gene expression, typi-
cally require days for reversal of the effect.
Apart from serving as the basis for an experimental ap-
proach for protein level transient modulation, the study docu-
mented in this report underscores the puzzling phenomenon
of reduction in the PrP level in response to oligonucleotide
contact. The biological significance of membrane-anchored
PrP susceptibility to oligodeoxynucleotides is poorly under-
stood. It is tempting to speculate that this universal and highly
conserved process, as emerging from the present study, is rel-
evant to physiological states in which PrP down-regulation is
imperative and which implicate the contact of PrP with short
DNA fragments. The presence of extracellular DNA may pre-
vent the detrimental release of PrP. The quantitative ap-
proach adopted in this study may contribute to future eluci-
dation of this phenomenon.
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